Webcast CME

Series Activities

Series Menu

Biologic Therapies Summit IX: Immune-based Inflammatory Diseases Through the Lens of COVID-19 and Specific Questions in Vasculitis Treatment

What dose and duration of glucocorticoids should be used in ANCA-associated vasculitis?

Print this Content

Release date: August 20, 2021
Expiration date: August 20, 2023

Estimated Time of Completion: 30 minutes

Description

In the Biologic Therapies Summit IX: Immune-based Inflammatory Diseases Through the Lens of COVID-19 and Specific Questions in Vasculitis Treatment online series, an international, multi-disciplinary faculty of experts focuses on immune-mediated disease, with a focus on new perspectives due to COVID-19. Additionally, there is a focus on vasculitis and factors that influence the selection of treatments for vasculitis disorders.

What dose and duration of glucocorticoids should be used in ANCA-associated vasculitis? webcast highlights issues related to the use of glucocorticoids in the treatment of ANCA-associated vasculitis.

Learning Objectives

  1. Review the issues and controversies regarding use of glucocorticoids in the treatment of ANCA-associated vasculitis.
  2. Discuss the findings and implications of recent clinical trials studying different dosing regimens of glucocorticoids the treatment of ANCA-associated vasculitis.
  3. Outline current research in the field of ANCA-associated vasculitis addressing the dosing of glucocorticoids.

Target Audience

The online series is designed for rheumatologists, dermatologists, infectious disease physicians, allergists, clinical immunologists, as well as specialists in integrative medicine, preventive medicine, wellness, primary care, and other health care professionals caring for patients with vasculitis and immune-mediated inflammatory diseases.

Accreditation

The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Cleveland Clinic Foundation Center for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.


American Board of Internal Medicine MOC

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Your credit will be reported to the ABIM within 30 days of claiming credit.

Activity Director and Faculty

Activity Directors

Cassandra Calabrese, DO
Department of Rheumatic and Immunologic Diseases
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH

Leonard H. Calabrese, DO
Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Department of Rheumatic and Immunologic Diseases
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH

M. Elaine Husni, MD, MPH
Director, Arthritis and Musculoskeletal Treatment Center
Vice Chair, Department of Rheumatic and Immunologic Diseases
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH

Carol Langford, MD, MHS, FACP
Director, Center for Vasculitis Care and Research
Department of Rheumatic and Immunologic Diseases
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH

Faculty


Peter Merkel, MD, MPH
Chief, Division of Rheumatology
Professor of Medicine
University of Pennsylvania
Philadelphia, PA


CME Disclaimer

The information in this educational activity is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition. The viewpoints expressed in this CME activity are those of the authors/faculty. They do not represent an endorsement by The Cleveland Clinic Foundation. In no event will The Cleveland Clinic Foundation be liable for any decision made or action taken in reliance upon the information provided through this CME activity.

Disclosures

In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias. 

The following faculty have indicated that they may have a relationship, which in the context of their presentation(s), could be perceived as a potential conflict of interest:

Leonard H. Calabrese, DO Abbvie Pharmaceuticals, BMS, Genentech/Roche, Janssen, Novartis Consulting
Teaching and Speaking
Astra Zeneca, Crescendo Teaching and Speaking
GSK, Regeneron, Sanofi Aventis, UCB Consulting
M. Elaine Husni, MD Abbvie Pharmaceuticals, Amgen, Bristol-Myers Squibb Co., Janssen, Lilly, Regeneron Consulting
Membership on advisory committee or review panels
Genenetch, UCB, Inc. Consulting
Novartis Pharmaceuticals Consulting
Membership on advisory committee or review panels
Teaching and Speaking
Pfizer, Inc. Membership on advisory committee or review panels
WebMD Consulting
Teaching and Speaking
Carol Langford, MD Abbvie Pharmaceuticals Non-paid consultant for research
Astrazeneca Pharmaceuticals, Bristol-Myers Squibb Co. Non-paid consultant for research
Clinical trial funding support
Chemocentryx, Genenetch, GlaxoSmithKline Clinical trial funding support
Peter Merkel, MD

Abbvie Pharmaceuticals

Consulting
Research / Independent Contractor

Bristol-Myers Squibb Co.

Consulting
Research / Independent Contractor

Chemocentryx

Consulting
Research / Independent Contractor

GSK

Consulting
Research / Independent Contractor

Genentech/Roche

Consulting
Research / Independent Contractor

Boehringer Ingelheim

Consulting
Research / Independent Contractor

CSL Behring

Consulting

Forbius

Consulting
Research / Independent Contractor

Genzyme/Sanofi

Consulting
Research / Independent Contractor

Janssen

Consulting

InflaRx

Consulting
Research / Independent Contractor

Kiniksa Pharmaceuticals

Consulting

Kyverna

Consulting

Magenta Therapeutics

Consulting

Novartis

Consulting

Pfizer

Consulting

Sparrow Pharmaceuticals

Consulting

Takeda

Consulting
Research / Independent Contractor

Talaris Therapeutics

Consulting

Astra Zeneca

Consulting
Research / Independent Contractor

Uptodate

Royalties

The following faculty have indicated she has no relationship which, in the context of her presentation(s), could be perceived as a potential conflict of interest:

Cassandra Calabrese, DO

The Cleveland Clinic Foundation Center for Continuing Education
acknowledges educational grants for partial support of the Internet Enduring activity from:

AbbVie, Inc.
Bristol-Myers Squibb Company
Genentech USA, Inc.
Janssen Scientific Affairs, LLC
Novartis Pharmaceuticals Corporation
UCB, Inc.

The Cleveland Clinic Foundation Center for Continuing Education
acknowledges educational grants for partial support of the Live activity from:

AbbVie, Inc.
Bristol-Myers Squibb Company
Genentech USA, Inc.
Janssen Scientific Affairs, LLC
Lilly USA, LLC
Novartis Pharmaceuticals Corporation
Pfizer Inc.
UCB, Inc.

 


This CME activity was produced by the Cleveland Clinic Center for Continuing Education
and Cleveland Clinic's RJ Fasenmyer Center for Clinical Immunology.